Serum uric acid in patients with acute ST-elevation myocardial infarction

BACKGROUND:Few studies investigated serum uric acid levels in patients with acute STelevation myocardial infarction(STEMI).The study was to assess the clinical value of serum uric acid levels in patients with acute ST-elevation myocardial infarction(STEMI).METHODS:Totally 502 consecutive patients with STEMI were retrospectively studied from January 2005 to December 2010.The level of serum lipid,echocardiographic data and in-hospital major adverse cardiovascular events(MACE) in patients with hyperuricemia(n=119) were compared with those in patients without hyperuricemia(n=383).The relationship between the level of serum uric acid and the degree of diseased coronary artery was analyzed.All data were analyzed with SPSS version 17.0 software for Student's t test,the Chi-square test and Pearson's correlation coefficient analysis.RESULTS:Serum uric acid level was positively correlated with serum triglyceride level.Hyperlipidemia was more common in hyperuricemia patients than in non-hyperuricemia patients(43.7%vs.33.7%,P=0.047),and serum triglyceride level was significantly higher in hyperuricemia patients(2.11±1.24 vs.1.78±1.38,P=0.014).But no significant association was observed between serum uric acid level and one or more diseased vessels(P>0.05).Left ventricular end-diastolic diameter(LVEDd) was larger in hyperuricemia patients than in non-hyperuricemia patients(53.52±6.19 vs.52.18±4.89,P=0.041).The higher rate of left systolic dysfunction and diastolic dysfunction was discovered in hyperuricemia patients(36.4%vs.15.1%,P<0.001;68.2%vs.55.8%,P=0.023).Also,hyperuricemia patients were more likely to have in-hospital MACE(P<0.05).CONCLUSIONS:Serum uric acid level is positively correlated with serum triglyceride level,but not with the severity of coronary artery disease.Hyperuricemia patients with STEMI tend to have a higher rate of left systolic dysfunction and diastolic dysfunction and more likely to have more in-hospital MACE.

Correlation of serum iron levels with myocardial injury and pump failure in patients with acute ST-elevation myocardial infarction

Objective:To analyze the correlation of serum iron levels with myocardial injury and pump failure in patients with acute ST-elevation myocardial infarction. Methods:80 patients with acute ST-elevation myocardial infarction were divided into high iron group (serum iron≥8.95μmol/L) (n=43) and low iron group (serum iron<8.95μmol/L) (n=37) according to serum iron levels, differences in myocardial injury markers, ventricular remodeling indexes and pump failure-related indexes on admission were compared between two groups of patients, and the correlation of serum iron levels with myocardial damage and pump failure in patients with acute ST-elevation myocardial infarction was further analyzed. Results:Serum myocardial injury markers troponin I (cTnI), creatine kinase isoenzyme (CK-MB), myoglobin (Myo), ischemia modified albumin (IMA) and hydroxybutyrate dehydrogenase (HBDH) content of high iron group on admission were significantly lower than those of low iron group (P<0.05);left ventricular posterior wall thickness (LVPWT), left ventricular end-systolic interventricular septal thickness (IVST), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), end-systolic volume index (ESVI), end-diastolic volume index (EDVI), and the left ventricular mass index (LVMI) levels under color Doppler ultrasound were lower than those of low iron group (P<0.05);serum N-terminal pro-brain natriuretic peptide (NT-proBNP), galectin-3, adiponectin (APN), soluble P-selectin (sP-selectin) and Copeptin content were lower than those of low iron group (P<0.05). Pearson test showed that serum iron level was directly correlated with the degree of myocardial injury and pump failure in patients with acute ST-elevation myocardial infarction. Conclusions:Low serum iron levels is one of key factors causing severe cases and pump failure in STEMI patients, and early iron supplementation is expected to improve outcomes in STEMI patients with iron deficiency.

Effects of intracoronary injection of nicorandil and tirofiban on myocardial perfusion and short-term prognosis in elderly patients with acute ST-segment elevation myocardial infarction after emergency PCI

BACKGROUND:This study investigated the effects of the intracoronary injection of nicorandil and tirofiban on myocardial perfusion and short-term prognosis in elderly patients with acute ST-segment elevation myocardial infarction(STEMI)after emergency percutaneous coronary intervention(PCI).METHODS:Seventy-eight STEMI patients with age>65 years who underwent emergency PCI were consecutively enrolled.These patients received conventional PCI and were randomly divided into a control group and a treatment group(n=39 per group).The control group received an intracoronary injection of tirofiban followed by a maintenance infusion for 36 hours after surgery.The treatment group received intracoronary injection of tirofiban and nicorandil,and then intravenous infusion of tirofiban and nicorandil 36 hours after surgery.The following parameters were measured:TIMI grade,corrected TIMI frame count(c TFC),TIMI myocardial perfusion grade(TMPG),STsegment resolution(STR)rate 2 hours post-operatively,resolution of ST-segment elevation(STR)at 2 hours postoperatively,peak level of serum CK-MB,left ventricular end diastolic diameter(LVEDD)and left ventricular ejection fraction(LVEF)at 7–10 days postoperatively,and major adverse cardiac events(MACEs)in-hospital and within 30 days post-operatively.RESULTS:Compared with the control group,more patients in the treatment group had TIMI 3 and TMPG 3,and STR after PCI was significantly higher.The treatment group also had significantly lower c TFC,lower infarction relative artery(IRA),lower peak CK-MB,and no reflow ratio after PCI.The treatment group had significantly higher LVEDD and LVEF but lower incidence of MACEs than the control group.CONCLUSION:The intracoronary injection of nicorandil combined with tirofiban can effectively improve myocardial reperfusion in elderly STEMI patients after emergency PCI and improve shortterm prognoses.

Combination therapy reduces the percutaneous coronary intervention acute myocardial infarction incidence of no-reflow after primary in patients with ST-segment elevation

Background No-reflow is associated with an adverse outcome and higher mortality in patients with ST-segment elevation acute myocardial infarction （STEMI） who undergo percutaneous coronary intervention （PCI） and is considered a dynamic process characterized by multiple pathogenetic components. The aim of this study was to investigate the effectiveness of a combination therapy for the prevention of no-reflow in patient with acute myocardial infarction （AMI） undergoing primary PCI. Methods A total of 621 patients with STEMI who underwent emergency primary PCI were enrolled in this study. Patients with high risk of no-reflow （no-flow score 〉 10, by using a no-flow risk prediction model, n = 216） were randomly divided into a controlled group （n = 108） and a combination therapy group （n = 108）. Patients in the controlled group received conventional treatment, while patients in combination therapy group received high-dose （80 mg） atorvastatin pre-treatment, intracoronary administration of adenosine （140 ~tg/min per kilogram） during PCI procedure, platelet membrane glycoprotein lib/Ilia receptor antagonist （tirofiban, 101.tg/kg bolus followed by 0.15 ~tg/kg per minute） and thrombus aspiration. Myocardial contrast echocardiography was performed to assess the myocardial perfusion 72 h after PCI. Major adverse cardiac events （MACE） were followed up for six months. Results Incidence of no-reflow in combination therapy group was 2.8%, which was similar to that in low risk group 2.7% and was significantly lower than that in control group （35.2%, P 〈 0.01）. The myocardial perfusion （A= 13） values were higher in combination therapy group than that in control group 72 h after PCI. After 6 months, there were six （6.3%） MACE events （one death, two non-fatal MIs and three revasculafizations） in combination therapy group and 12 （13.2%） （four deaths, three non-fatal MIs and five revascularizations, P 〈 0.05） in control group. Conclusions Combination of thrombus aspiration, high-dose statin pre-treatment, intmcoronary administration of adenosine during PCI procedure and platelet membrane glycoprotein Ⅱ b/Ⅲa receptor antagonist reduces the incidence of no-reflow after primary PCI in patients with acute myocardial infarction who are at high risk of no-reflow.

Efficacy and safety of single-bolus tenecteplase compared with front-loaded alteplase in Chinese patients with acute myocardial infarction

Following ST-segment elevation myocardial infarction(STEMI), early and complete epicardial reperfusion is associated with improved survival.……

The impact analysis of the oxidative stress injury and inflammatory factor level for ticagrelor assisted PCI in the treatment the elderly patients with ST segment elevation acute myocardial infarction

Objective:To investigate the effect of ticagrelor assisted PCI in treatment the elderly patients with acute ST elevation myocardial infarction (STEMI) on oxidative stress and inflammatory factor level.Methods:A total of 100 cases elderly patients with STEMI were selected that they were being treated with PCI. According to the digital list method was divided into the study group and control group, and 50 cases in each group. The control group was treated with PCI and the strong heart, anticoagulation, vasodilation, prevention of infection and other comprehensive treatment of myocardial infarction, the study group were given ticagrelor treatment which was based on the comprehensive treatment of myocardial infarction. The level change were compared that oxidative stress index (MDA), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) activity and inflammatory factor hypersensitive C reactive protein (hs-CRP), N-terminal pro brain natriuretic peptide (NT-proBNP) and interleukin -6 (IL-6) between the two groups in before treatment (T0), treatment with 7 d (T1), 14 d (T2), 30 d (T3).Results:(1)There was no significant difference in serum MDA, GSH-Px and SOD levels between the two groups in the T0. Two groups serum MDA level were higher than theT0, and the GSH-Px and SOD levels were lower than the T0 after operation in the T1.And the serum MDA level were lower than T0, T1, GSH-Px and SOD levels were higher than T0, T1in the T2, T3.The T3 serum MDA level was lower than T2, GSH-Px and SOD levels were higher than T2.Even the serum MDA was significantly lower than the control group T1, T2, T3 and the GSH-Px and SOD were higher than those of the control group T1, T2, T3 at the study groupT1, T2, T3, the difference was statistically significant. (2)There was no significant difference in T0 of the serum hs-CRP, IL-6 and NT-proBNP levels between the two groups. Two groups serum hs-CRP, IL-6 and NT-proBNP level were higher than the T0 after operation in the T1.And the serum hs-CRP, IL-6 and NT-proBNP levels were higher than T0, T1in the T2, T3.The T3 serum hs-CRP, IL-6 and NT-proBNP levels were lower than T2.and that the serum hs-CRP, IL-6 and NT-proBNP levels were significantly lower than the control group T1, T2, T3 at the study groupT1, T2, T3, so the difference was statistically significant.Conclusion:The treatment method will be able to reduce oxidative stress injury and effectively control the inflammatory response that ticagrelor assisted PCI in treatment the elderly patients with acute ST elevation myocardial infarction (STEMI).

The optimal timing for delayed percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction presenting beyond 12 hours after symptoms onset

Objective To evaluate the impact of the timing of delayed PCI on the outcomes of patients with STEMI missing out on early reperfusion therapy within 12 h after symptom onset and ascertain the eligible time window to perform delayed PCI.Methods Among 28,061 patients registered in China Acute Myocardial Infarction(CAMI)registry,a total of 3,048 stable patients with STEMI who did not underwent any early reperfusion therapy within 12 hours after symptom onset and received delayed PCI at recovery stage were finally enrolled.

Application of N-terminal pro-brain natriuretic peptide concentration and the Global Registry of Acute Coronary Events risk score to predict major adverse cardiac events in patients with ST-elevation myocardial infarction after PCI

Identifying patients with high risk of death after myocardial infarction is a cornerstone of modern cardiovascular health care.The purpose of this study was to explore the predictive ability of N-terminal probrain natriuretic peptide(NT-pro-BNP)concentration and global acute coronary event register(GRACE)risk score in the prognosis of ST-segment elevation myocardial infarction(STEMI)patients,to find a better method for early risk stratification and prognosis judgment in the clinical diagnosis and treatment of STEMI patients,and to provide reliable clinical basis for making the best individualized treatment strategies for patients.Methods The final analysis included 118 confirmed STEMI patients who had received acute percutaneous coronary intervention(PCI).Thirty patients with STEMI were included in the major cardiac adverse events(MACEs)group,and the rest were included in the non-MACEs group.Multivariate Cox regression analysis was used to assess the relationship between the risk factors and MACEs.The receiver operator curves(ROC)were used to determine the area under the statistical curve(AUC).The linear correlation analysis confirmed the relationship between NT-proBNP concentration and GRACE score.Results After adjustment for sex,history of current smoking,hypertension,diabetes mellitus,cerebral artery disease and coronary artery vessel lesion(single-vessel lesion,2-vessel lesion,3-vessel lesion),onset time and medication,the multivariate Cox’s regression analysis showed that NT-proBNP concentration and GRACE score were the independent predictors for MACEs in STEMI patients who received PCI.Linear regression analysis showed that the level of NT-pro-BNP was positively correlated with GRACE score(r=0.612,P=0.000).The area under the curve(AUC)for GRACE,NT-pro-BNP and their combination were 0.757,0.723 and 0.782,respectively.Conclusions In a one-year follow-up,the concentration of NTpro-BNP and GRACE score were valuable of prediction for MACEs in STEMI patients who received PCI.In addition,NT-pro-BNP concentration was positively correlated with GRACE score.Additionally,the concentration of NT-pro-BNP could moderately enhance the GRACE score prediction of 1-year MACEs in STEMI patients who received PCI.

Biomarkers enhance the long-term predictive ability of the KAMIR risk score in Chinese patients with ST-elevation myocardial infarction

Background:The Global Registry of Acute Coronary Events (GRACE) score is recommended by current ST-elevation myocardial infarction (STEMI) guidelines.But it has inherent defects.The present study aimed to investigate the more compatible risk stratification for Chinese patients with STEMI and to determine whether the addition of biomarkers to the Korea Acute Myocardial Infarction Registry (KAMIR) score could enhance its predictive value for long-term outcomes.Methods:A total of 1093 consecutive STEMI patients were included and followed up 48.2 months.Homocysteine,hypersensitive C-reactive protein (hs-CRP),and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were detected.The KAMIR score and the GRACE score were calculated.The performance between the KAMIR and the GRACE was compared.The predictive power of the KAMIR alone and combined with biomarkers were assessed by the receiver-operating characteristic (ROC) curve.Results:The KAMIR demonstrated a better risk stratification and predictive ability than the GRACE (death:AUC = 0.802 vs.0.721,P<0.001;major adverse cardiovascular events (MACE):AUC = 0.683 vs.0.656,P<0.001).It showed that the biomarkers could independently predict death [homocysteine:HR= 1.019 (1.015–1.024),P<0.001;hs-CRP:HR= 1.052 (1.000–1.104),P= 0.018;NT-pro BNP:HR= 1.142 (1.004–1.280),P= 0.021] and MACE [homocysteine:HR= 1.019 (1.015–1.024),P<0.001;hs-CRP:HR= 1.012 (1.003–1.021),P= 0.020;NT-pro BNP:HR= 1.136 (1.104–1.168),P= 0.006].When they were used in combination with the KAMIR,the area under the ROC curve (AUC) significantly increased for death [homocysteine:AUC = 0.802 vs.0.890,Z = 5.982,P<0.001;hs-CRP:AUC = 0.802 vs.0.873,Z= 3.721,P<0.001;NT-pro BNP:AUC= 0.802 vs.0.871,Z = 2.187,P= 0.047;homocysteine,hs-CRP and NT-pro BNP:AUC = 0.802 vs.0.940,Z = 6.177,P<0.001] and MACE [homocysteine:AUC = 0.683 vs.0.771,Z= 6.818,P<0.001;hs-CRP:AUC= 0.683 vs.0.712,Z= 2.022,P= 0.031;NT-pro BNP:AUC= 0.683 vs.0.720,Z= 2.974,P= 0.003;homocysteine,hs-CRP and NT-pro BNP:AUC= 0.683 vs.0.789,Z= 6.900,P<0.001].Conclusion:The KAMIR is better than the GRACE in risk stratification and prognosis prediction in Chinese STEMI patients.A combination of above-mentioned biomarkers can develop a more predominant prediction for long-term outcomes.

Percutaneous treatment in acute coronary syndromes

Both ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndromes (ACS) are the result of an acute thrombotic lesion obstructing blood flow in the coronary vasculature. Percutaneous treatment has shown to improve clinical outcome in this clinical setting by resolving coronary obstruction with different devices directed to restore coronary blood flow. In comparison with balloon alone angioplasty, implantation of bare metal stents reduced the rate of restenosis and cardiac events, but high rates of restenosis remained, leading to further investigations to develop drug-eluting stents with different pharma- cological coatings that reduced restenosis rates and clinical events. In this review, we discuss the current treatment of ACS, reviewing recent randomized clinical trials and advances in medical treatment, including new antiplatelet agents and recent guideline recommendations.

胸部CT冠状动脉钙化积分与STEMI患者急诊PCI围术期并发症的相关性研究

目的:探讨胸部CT冠状动脉钙化积分(CAC)与急性ST段抬高型心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)围术期并发症的相关性。方法:选取2020年3月至2021年7月保定市第一中心医院心内科收治的263例STEMI患者,均行胸部CT检查和PCI手术,评估CAC积分,并根据CAC积分将患者分成无钙化和轻度钙化组(0~2分,129例)、中度钙化组(3~5分,88例)及重度钙化组(6~9分,46例),分析不同程度钙化组患者围术期并发症及随访期主要心血管事件(MACE)发生情况,比较各组差异并分析其与急诊PCI围术期并发症的相关性。结果:与无钙化和轻度钙化组相比,中度和重度钙化组患者年龄更大,差异有统计学意义(χ^(2)=45.815,P<0.05),高血压、脑梗死、糖尿病、多支病变和MACE的发病率更高,差异有统计学意义(χ^(2)=6.762、11.071、6.064、25.036、21.694,P<0.05)。3组患者eGFR及NT-ProBNP水平比较,差异有统计学意义(F=8.592,Z=20.890,P<0.05)。与重度钙化组相比,无钙化和轻度钙化组冠状动脉血栓发生率较高(χ^(2)=7.748,P<0.05)。根据logistic回归分析,冠状动脉血栓、中度钙化及重度钙化患者是出现轻微并发症的危险因素(OR=4.847、5.280、11.135,P<0.001);年龄越大、患有高血压或冠状动脉重度钙化患者更容易出现严重并发症,术后1年内MACE发生率更高,是围术期并发症的危险因素(OR=1.151、7.982、10.555、21.729,P<0.05)。结论:胸部CT的CAC积分评估出的中度及重度钙化病变患者的围术期并发症发生率更高,基于胸部CT的CAC积分可用于评估急诊PCI围术期的并发症及术后1年内MACE。

The impact of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention

Objective To investigate the effects of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction(STEMI)patients after emergency percutaneous coronary intervention(PCI).Methods A total of 120 patients with acute STEMI treated with emergency PCI were enrolled and randomly divided into 20 mg of atorvastatin treatment group(standard group,n=60),and 40 mg of atorvastatin treatment group(intensive group,n=60).

GRACE评分联合WMR对STEMI患者急诊PCI术后发生院内MACE的预测价值

目的 探讨全球急性冠状动脉事件注册(GRACE)评分联合白细胞(WBC)计数与平均血小板体积比(WMR)对急性ST段抬高型心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)术后发生院内主要不良心血管事件(MACE)的预测价值。方法 回顾性分析2021年1月至2022年3月于襄阳市中心医院接受急诊PCI治疗的349例STEMI患者临床资料。根据院内MACE发生情况,将患者分为MACE组(n=47)和非MACE组(n=302)。比较不同分组患者的临床资料,采用Cox回归分析STEMI患者PCI术后发生院内MACE的危险因素,采用ROC曲线分析评估GRACE评分联合WMR对STEMI患者PCI术后发生院内MACE的预测价值。结果 与非MACE组相比,MACE组年龄较大,收缩压、舒张压和左心室射血分数(LVEF)较低;心率、Killip分级≥Ⅱ的比率、GRACE评分、WBC、WMR、中性粒细胞与淋巴细胞比值(NLR)、空腹血糖(FPG)、肌酐(Cr)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)和肌酸激酶MB同工酶(CK-MB)较高,差异均有统计学意义(P<0.05)。多因素Cox回归分析结果显示,较高的GRACE评分和WMR是促进STEMI患者发生院内MACE的独立危险因素(P<0.05)。ROC曲线分析结果显示,GRACE评分和WMR均能有效预测STEMI患者PCI术后发生院内MACE(P<0.05),且两者联合的预测效能更优[AUC(95%CI)=0.824(0.750~0.897),P<0.001],灵敏度和特异度分别为74.50%、80.50%。结论 GRACE评分联合WMR对STEMI患者PCI术后发生院内MACE具有良好的预测价值,有助于临床工作者进行更精准的风险分层和治疗决策制定。

胸痛中心建设对急性STEMI患者救治的影响

目的探讨胸痛中心建设对急性ST段抬高型心肌梗死(STEMI)患者救治效率的影响。方法连续入组2015年3月至2018年12月于酒泉市人民医院心内科STEMI患者542例,按入组时间接受治疗不同,相应分为三组:导入期148例、干预期149例及胸痛中心运行期245例。比较三组患者来源,急救处置情况(首份心电图时间、首次心电-签署知情时间、签署知情-穿剌时间,是否绕行急诊、CCU,门-球时间、发病-球囊扩张时间、D2B达标率、使用药物);及治疗后情况(并发症、住院时间、院内及出院半年死亡情况)。结果三组患者来源有统计学差异,胸痛中心运行期外院转入患者明显较多(P<0.05)。三组首份心电图时间、首次心电-签署知情时间、签署知情-穿剌时间,绕行CCU例数、绕行急诊和CCU例数,D2B时间、D2B达标率、发病-球囊扩张时间,入院24 h内阿司匹林、波立维和肝素使用占比,院内β受体阻滞剂、他汀类药物和ACEI/ARB占比、出院半年死亡例数均有统计学差异(P均<0.05)。其中,胸痛中心运行期首份心电图时间、首次心电-签署知情时间、签署知情-穿剌时间,绕行CCU例数、绕行急诊和CCU例数,D2B时间、D2B达标率、发病-球囊扩张时间明显优于其它两组(P均<0.05)。其余指标组间相近(P均>0.05)。结论胸痛中心建设可有效提高急性STEMI患者救治效率。

替格瑞洛与氯吡格雷治疗急性STEMI合并糖尿病患者疗效观察

目的比较替格瑞洛与氯吡格雷治疗急性ST段抬高型心肌梗死(STEMI)合并糖尿病患者的临床疗效。方法采用回顾性分析的方法,选择我院2013年1月至2014年2月期间收治的行急诊经皮冠状动脉介入(PCI)且接受替格瑞洛联合阿司匹林治疗的157例急性STEMI合并糖尿病患者作为观察组;选择我院2012年1月至2013年1月期间收治的行急诊PCI术后接受氯吡格雷联合阿司匹林治疗的150例急性STEMI合并糖尿病患者作为对照组,比较两组患者治疗前后的血小板相关指标、主要不良心血管事件、心绞痛、再发心梗的累积发生率,以及治疗后不同时间段内主要安全重点事件的累积发生率。结果两组患者的临床一般资料比较差异均无统计学意义(P>0.05);治疗1周后,对照组与观察组的血小板聚集率分别为(58.23±4.21)%和(55.26±3.91)%,均较治疗前明显下降,且观察组明显低于对照组(P<0.05);治疗1周后,对照组与实验组患者的血小板计数分别为(187.63±23.92)×109/L和(220.76±20.82)×109/L,均较治疗前明显上升,且观察组明显高于对照组(P<0.05);治疗1周后,对照组和观察组患者的主要不良心血管事件发生率分别为2.7%(4/150)和0(0/157),观察组明显低于对照组(P<0.05);治疗1周后,对照组和观察组患者的总体出血累积发生率分别为0(0/150)和1.9%(3/157),观察组明显高于对照组(P<0.05),但致命出血累计发生率两组比较差异无统计学意义(P>0.05)。结论急性STEMI合并糖尿病患者应用替格瑞洛治疗较氯吡格雷能够发挥更好的抗血小板聚集作用,且能减少术后不良心血管事件发生率,降低术后致命出血累积发生率,具有较好的治疗效果,值得临床推广应用。

老年STEMI病人介入治疗门-球时间延误的相关因素分析

[目的]探讨老年急性ST段抬高型心肌梗死(STEMI)病人门-球时间(DTB)延误状况及其影响因素。[方法]回顾2015年6月—2016年12月在镇江市某三级甲等医院行急诊PCI的125例老年急性STEMI病人的相关资料,分析其DTB延误状况及相关因素。[结果]125例病人中DTB>90min者36例,占28.8%。单因素分析结果显示性别、糖尿病史、病变血管支数、入院时间、入院—首次心电图时间、首次心电图—决定PCI时间、决定PCI—知情同意时间、启动导管室—球囊扩张时间是老年急性STEMI病人DTB延误的影响因素(P<0.05)。对有统计学意义的8个变量进行Logistic回归分析结果显示,病变血管支数、入院时间、入院—首次心电图时间、决定PCI—知情同意时间是老年急性STEMI病人DTB>90min的独立危险因素。[结论]通过分析老年STEMI病人介入治疗DTB延误的影响因素,可为改善医院就诊流程,缩短DTB,改善病人预后提供参考依据。

三种心电图标准对疑似ACS合并完全性左束支传导阻滞时被视为STEMI等危征的诊断价值

目的 探讨使用三种心电图诊断标准对急诊科拟诊为急性冠脉综合征(ACS)患者合并完全性左束支传导阻滞(CLBBB)时被视为ST段抬高型心肌梗死(STEMI)等危征,最终经急诊冠脉造影证实发生急性心肌梗死的诊断能力。方法 回顾性分析41例在急诊科拟诊为ACS合并CLBBB的患者,均经急诊完善冠脉造影后收入心内科重症监护单元(CCU),最终诊断分为AMI组(n=15)和非AMI组(n=26),分别使用巴塞罗那标准、Sgarbossa标准和Smith标准对两组患者心电图进行评测,绘制各诊断标准受试者工作特征(ROC)曲线,并得出ROC曲线下面积(AUC),分别计算敏感度(SEN)、特异度(SPE)、阳性预测值(PPV)、阴性预测值(NPV)和准确度(CP),并进行解读。结果 巴塞罗那标准对在急诊科拟诊为ACS患者合并CLBBB时,经急诊冠脉造影证实诊断并治疗的AMI的AUC为0.947(P<0.001),其SEN、SPE、PPV、NPV、CP分别为92.9%、92.0%、86.7%、95.8%、92.3%;Sgarbossa≥3标准诊断AMI的AUC为0.647(P=0.120),其SEN、SPE、PPV、NPV、CP分别为35.7%、96.0%、83.3%、72.7%、74.4%;Sgarbossa≥2标准诊断AMI的AUC为0.604(P=0.273),其SEN、SPE、PPV、NPV、CP分别为42.9%、84.0%、60.0%、72.4%、69.2%;SmithⅢ标准诊断AMI的AUC为0.795(P=0.002),其SEN、SPE、PPV、NPV、CP分别为71.4%、92.0%、83.3%、85.2%、84.6%;SmithⅣ标准诊断AMI的AUC为0.656(P=0.099),其SEN、SPE、PPV、NPV、CP分别为50.0%、84.0%、63.6%、75.0%、71.8%;SmithⅤ标准诊断AMI的AUC为0.614(P=0.228),其SEN、SPE、PPV、NPV、CP分别为28.6%、96.0%、80.0%、70.6%、71.8%。巴塞罗那标准对在急诊科拟诊为ACS患者合并CLBBB时经急诊冠脉造影证实,诊断AMI的AUC、SEN、SPE、PPV、NPV、CP均高于Sgarbossa标准和Smith标准(P<0.001)。结论 急诊科拟诊为ACS合并CLBBB的患者中,应用心电图的巴塞罗那标准诊断AMI具有准确、简洁、实用的特点。

伴IGT的STEMI患者行PCI前后血清MIP-1α的变化及阿卡波糖的干预价值

目的探讨伴糖耐量降低（IGT）的ST段抬高型急性心肌梗死（STEMI）患者行经皮冠状动脉介入治疗（PCI）前后血清巨噬细胞炎症蛋白1α（MIP—1α）的变化及阿卡波糖对其干预价值。方法选择拟行PCI的STEMI患者160例，设为A组。依据是否合并IGT，再将分入A，组（伴IGT者）和A2组（不伴IGT者），随机将A，组等分人A1a组和A1b组；选取健康志愿者30例，设为B组。A组行标准PCI术，A1a组自PCI后另予阿卡波糖治疗，连续6个月。A组于PCI前（T0）、PCI后24h（T1）、PCI后6个月（T2）；B组于体检当日，采用双抗体夹心酶联免疫吸附试验（ELISA）测定血清MIP—1α水平。A1组、A2组均于T0时间点，A1组另于T2时间点，行超声心动图检查了解左心室结构和功能。结果A组中，伴IGT的STEMI患者构成比为71．25％。T0时间点，A组血清MIP-1α水平显著高于B组（t=7．37，P〈0．01），A1组高于A2组（t=4．63，P〈0．05）；T1时间点，A组血清MIP—1α水平均升高（t-3．65—4．77，P〈0．05），A1组高于A2组水平（t=5．21，P〈0．05）；T2时间点，A组血清MIP—1α均显著降低（t=6．13—7．62，P〈0．01），且A1a组血清MIP—1α低于A1b组（t=4．06，P〈0．05）。T2时点，A1a组、A1组的LVD、LVMI减小，LVEF增大（t=3．67—6．21，P〈0．05或P〈0．01），A1b组的LVMI减小，LVEF增大（tLVMI=3．53，tLVEF=3．85，P〈0．05）；且A1a组LVD、LVMI数值低于A1b组，LVEF数值高于A1b组（t=3．40～4．12，P〈0．05）。结论伴IGT的STEMI患者血清MIP-1α水平显著高于健康人群，行PCI术后呈一过性升高，其后逐渐降低。对伴IGT的STEMI患者予以阿卡波糖干预治疗，能进一步降低血清MIP-1α水平，缓解机体炎症反应程度，改善左心室结构和功能，这对于伴IGT的STEMI患者临床诊疗具有一定的借鉴意义和参考价值。

替格瑞洛联合阿司匹林对老年STEMI患者PCI术后冠状动脉血流及血小板聚集率的影响

目的:探讨替格瑞洛联合阿司匹林在老年急性ST段抬高型心肌梗死(STEMI)行经皮冠状动脉介入治疗术(PCI)患者中的应用效果。方法:选取86例老年STEMI患者,将其随机分为对照组和观察组。对照组43例,采用阿司匹林;观察组43例,加用替格瑞洛。两组均连续用药3个月后,比较两组凝血功能指标、冠状动脉血流状况、血小板聚集率(MPAR)及不良反应发生情况。结果:观察组FIB水平高于对照组,PT、APTT短于对照组,差异有统计学意义(P<0.05);观察组冠状动脉血流状况优于对照组,MPAR水平低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率相比,差异无统计学意义(P>0.05)。结论:替格瑞洛联合阿司匹林能够改善老年STEMI患者凝血功能及冠状动脉血流状况,降低MPAR,安全性高。

择期经皮冠状动脉介入治疗与即刻经皮冠状动脉介入治疗对有TIMI3级血流STEMI患者临床疗效和安全性的对比研究

目的对TIMI3级急性ST段抬高型心肌梗死(STEMI)患者行即刻经皮冠状动脉介入治疗(PCI)与择期PCI临床疗效及安全性评价。方法 86例经急诊冠脉造影显示TIMI3级血流的STEMI患者,随机分为即刻PCI组(44例)及择期(7～10 d后)PCI组(42例)。对两组患者术中支架植入成功率、术中慢血流或无复流事件发生率、住院期心血管事件发生率、住院时间及术后4周左室射血分数(LVEF)比较。结果择期PCI组支架植入成功率100%,显著高于即刻PCI组88.64%,有显著性差异(P<0.05);术中慢血流或无复流事件的发生率即刻PCI组为11.36%,择期PCI组无1例发生,有显著性差异(P<0.05);住院期心血管事件发生率即刻PCI组为4.54%,择期PCI组为0,有显著性差异(P<0.05);术后4周两组患者LVEF及住院时间比较无显著性差异(P>0.05)。结论对TIMI3级血流的STEMI患者行择期PCI比即刻PCI有较好的临床疗效,且安全性明显提高。